Estimating the willingness to pay for a quality- adjusted life year in Thailand: Does the context of health gain matter?

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 29-36

  Thavorncharoensap, Montarat ^a,b   Teerawattananon, Yot ^b   Natanant, Sirin ^b   Kulpeng, Wantanee ^b   Yothasamut, Jomkwan ^b   Werayingyong, Pitsaphun ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Ceiling threshold; Health resource allocation; Time trade off; Visual analog scale

Indexed keywords

ADULT; ALLERGY; ANALYTIC METHOD; ARTICLE; ATTITUDE TO HEALTH; BLINDNESS; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; GENDER; HEALTH BEHAVIOR; HEALTH CARE; HEALTH SURVEY; HUMAN; INTERVIEW; MALE; MEDICAL DECISION MAKING; PARAPLEGIA; QUADRIPLEGIA; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SOCIAL STATUS; THAILAND; TIME TRADE OFF; VISUAL ANALOG SCALE; WILLINGNESS TO PAY;

EID: 84872692347     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S38062     Document Type: Article

References (36)

1. Sloan FA. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press; 1995.
2. WHO Commission on Macroeconomics and Health. Investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
3. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178.
4. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342.
5. Ubel P, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641.
6. Mason H, Baker R, Donaldson C. Willingness to pay for a QALY: past, present, and future. Expert Rev Pharmacoecon Outcomes Res. 2008;8(6):575-582.
7. Brouwer W, van Exel J, Baker R, et al. The new myth: the social value of the QALY. Pharmaco Economics. 2008;26(1):1-4.
8. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmaco Economics. 2005;23(5):423-432.
9. Johnson FR. Einstein on willingness to pay per QALY: is there a better way? Med Decis Making. 2005;25(6):607-608.
10. Lieu TA, Ray GT, Ortega-Sanchez IR, et al. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmaco Economics. 2009;27(12):1005-1016.
11. Donaldson C, Baker R, Mason H, et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res. 2011;11(8). Available from: http://www.biomedcentral.com/1472-6963/11/8. Accessed July 10, 2012.
12. Bobinac A, van Exel NJ, Rutten FF, et al. Willingness to pay for a quality-adjusted life year: the individual perspective. Value in Health. 2010;13(8):1046-1055.
13. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value in Health. 2009;12(s1):S10-S15.
14. Zhao FL, Yue M, Yang H, et al. Willingness to pay per qualityadjusted life year: is one threshold enough for decision-making? Results from a study in patients with chronic prostatitis. Med Care. 2011;49(3):267-272.
15. O Brien BJ, Gertsen K, Willan AR, et al. Is there a kink in consumer's threshold value for cost-effectiveness in health care? Health Econ. 2002;11(12):175-180.
16. Lee GM, Salomon JA, Gay C, et al. Preferences for health outcomes associated with group A streptococcal disease and vaccination. Health and Quality of Life Outcomes. 2010;8(1). Available from: http://www. hqlo.com/content/8/1/28. Accessed August 10, 2011.
17. Byrne MM, O'Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making. 2005;25(6):655-666.
18. Cunningham SJ, Hunt NP. Relationship between utility values and willingness to pay in patients undergoing orthognathic treatment. Community Dent Health. 2000;17(2):92-96.
19. King JT, Tsevat J, Lave JR, et al. Willingness to pay for a qualityadjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667-677.
20. Zethraeus N. Willingness to pay for hormone replacement therapy. Health Econ. 1998;7(1):31-38.
21. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003;12(1):1049-1060.
22. Donaldson C, Baker R, Mason H, et al. European Value of a Quality Adjusted Life Year. Final publishable report. 2010. http://research.ncl. ac.uk/eurovaq/EuroVaQ_Final_Publishable_Report_and_Appendices. pdf. Accessed March 20, 2011.
23. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422-437.
24. Jirawattanapisal T, Kingkaew P, Lee TJ, et al. Evidence-based decisionmaking in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value in Health. 2009;12(s3): S4-S11.
25. Vaughan WJ, Russell CS, Darling AH. Determining the optimal sample size for contingent valuation surveys. Tennessee: Department of Economics, Vanderbilt University; 2000.
26. International Monetary Fund. World Economic Outlook Database (WEO); 2010. http://www.imf.org/external/pubs/ft/weo/2010/01/weodata/index.aspx. Accessed January 5, 2012.
27. Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. Journal of the Medical Association of Thailand. 2008;91(s2):S43-S53.
28. Johannesson M, Jonsson B, Karlson G. Outcome measured in economic evaluation. Health Econ. 1996;5(4):279-296.
29. Nord E. Cost-value Analysis in Health Care. Making Sense Out of QALYs. New York: Cambridge University Press; 1999.
30. Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for costeffectiveness. Expert Rev Pharmacoecon Outcome Res. 2004;4(3): 247-250.
31. Freemantle N. Valuing the effects of sildenafil in erectile dysfunctions. Strong assumptions are required to generate a QALY value. Br Med J. 2000;320(7243):1156-1157.
32. Rheingans RD, Haddix AC, Messonnier ML, et al. Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti. Filaria J. 2004;3(1):2.
33. Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Economietrica. 1979;4:263-291.
34. Rasiel EB, Weinfurt KP, Schulman KA. Can prospect theory explain risk-seeking behavior by terminally ill patients? Med Decis Making. 2005;25(6):609-613.
35. Smith RD, Richardson J. Can we estimate the "social" value of a QALY? Four core issues to resolve. Health Policy. 2005;74(1):77-84.
36. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value in Health. 2009;12(s1):S5-S9.